Clinical Efficacy of Compound Biejia Ruangan Tablets Combined With Entecavir for the Treatment of Decompensated Chronic Hepatitis B-Related Cirrhosis: A Multiparameter Evaluation
| Author | Lixia Yu | en |
| Author | Mengjie Ma | en |
| Author | Jiacong Shen | en |
| Author | Yuwen Zhu | en |
| Author | Mingzhuan Chen | en |
| Author | Minghui Li | en |
| Author | Yiqing Zhou | en |
| Issued Date | 2026-12-31 | en |
| Abstract | Background: Chronic hepatitis B-related cirrhosis is a progressive liver disease that can lead to decompensation, recurrent portal hypertension-related events, impaired liver function, and poor long-term outcomes. Recompensation has recently been recognized as a clinically meaningful treatment goal in selected patients with decompensated cirrhosis. Compound Biejia Ruangan Tablets (CBRT), an antifibrotic traditional Chinese medicine formulation, may provide additional benefits when combined with antiviral therapy. Objectives: To evaluate the therapeutic efficacy and safety of CBRT in achieving recompensation after decompensation in chronic hepatitis B-related liver cirrhosis. Methods: Sixty individuals with chronic hepatitis B-related liver cirrhosis who experienced their first decompensation event were enrolled and randomly assigned to an observation group or a control group, with 30 patients in each group. The observation group received CBRT, four tablets per dose, three times daily, combined with one entecavir tablet nightly. The control group received one entecavir tablet in addition to standard diuretics and hepatoprotective medications. The treatment duration was 6 months in both groups. General conditions and clinical symptoms were recorded. Laboratory assessments included liver function tests, the FIB-4 index, platelet count, total protein, albumin, hepatitis B surface antigen titer, hepatitis B virus DNA, and four indices of liver fibrosis, which were measured before and after treatment. Decompensation events within 1 year and serious outcomes, including death and liver transplantation, were also recorded during follow-up. Results: Both the observation and control groups showed decreases in hepatitis B surface antigen titer, hepatitis B virus DNA load, and total bilirubin compared with pretreatment levels. Compared with the control group, the observation group showed greater improvements in albumin, FIB-4, liver fibrosis indices, and platelet count (P < 0.05). The incidence of decompensation events was higher in the observation group than in the control group, with minimal adverse events reported in both groups. Conclusions: As an adjunct to antiviral therapy for chronic hepatitis B-related liver cirrhosis, CBRT may help delay disease progression, reduce the risk of recurrent decompensation-related events, and improve liver function and clinical symptoms. These findings provide a useful reference for comprehensive clinical care. | en |
| DOI | https://doi.org/10.5812/hepatmon-171154 | en |
| Keyword | Compound Biejia Ruangan Tablets | en |
| Keyword | Chronic Hepatitis B | en |
| Keyword | Decompensated Liver Cirrhosis | en |
| Publisher | Brieflands | en |
| Title | Clinical Efficacy of Compound Biejia Ruangan Tablets Combined With Entecavir for the Treatment of Decompensated Chronic Hepatitis B-Related Cirrhosis: A Multiparameter Evaluation | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- hepatmon-26-1-171154-publish-pdf.pdf
- Size:
- 194.34 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF